In concordance with these observations, RNA splicing events are differentially rescued in DM1 preclinical models across a therapeutic dose range and have been shown to differentially respond to interventional knockdown of the DMPK transcript in a human clinical trial (24–29). The gene discussed is DMPK; the disease is myotonic dystrophy type 1.